Australia's Telix Pharmaceuticals rises on China acceptance of new drug application

Shares of Australia's Telix Pharmaceuticals TLX.AX rise as much as 6.3% to A$11.99, posting their biggest intraday pct gain in nearly two months

Stock touches its highest level since December-end

Biopharma co says the Chinese National Medical Products Administration (NMPA) has accepted New Drug Application (NDA) for its prostate cancer diagnosis agent, Illuccix

Says NDA submitted in association with partner Grand Pharmaceutical Group 0512.HK in Greater China region

Illuccix used as a scanning agent to detect prostate cancer in body

TLX among top gainers on the broader Australian benchmark index .AXJO, which is down 0.5%

TLX up 4.6% YTD after a 54.5% drop in 2025